Indeed, Decoster and colleagues recently reported that a genetic variation in the AKT1 gene may mediate cannabis-associated effects on the expression of psychosis via a cannabinoid-regulated AKT1/GSK-3 signaling mechanism that lies downstream of the dopamine D2 receptor (Decoster et al., 2011). This evidence concerns the gene AKT1 and psychotic disorder.